Zymedi’s first-in-class antibody treatment ZMA001, currently in development for pulmonary arterial hypertension (PAH), has been designated as an Orphan Drug by the U.S. Food and Drug Administration (FDA). Pulmonary arterial hypertension is an inflammatory vascular disease characterized by the remodeling and narrowing of pulmonary arterioles due to various causes. Currently, most treatments involve vasodilators, which only alleviate symptoms without providing a cure. Due to the diverse causes...